272 related articles for article (PubMed ID: 31764101)
1. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV.
Kim-Chang JJ; Donovan K; Loop MS; Hong S; Fischer B; Venturi G; Garvie PA; Kohn J; Rendina HJ; Woods SP; Goodenow MM; Nichols SL; Sleasman JW;
AIDS; 2019 Dec; 33(15):2363-2374. PubMed ID: 31764101
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
Eckard AR; Rosebush JC; O'Riordan MA; Graves CC; Alexander A; Grover AK; Lee ST; Habib JG; Ruff JH; Chahroudi A; McComsey GA
Antivir Ther; 2017; 22(8):669-680. PubMed ID: 28327462
[TBL] [Abstract][Full Text] [Related]
3. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection.
Lyons JL; Uno H; Ancuta P; Kamat A; Moore DJ; Singer EJ; Morgello S; Gabuzda D
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):371-9. PubMed ID: 21646912
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.
Williams JC; Zhang X; Karki M; Chi YY; Wallet SM; Rudy BJ; Nichols SL; Goodenow MM; Sleasman JW
J Leukoc Biol; 2018 Apr; 103(4):671-680. PubMed ID: 29377283
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya.
Temu TM; Zifodya JS; Polyak SJ; Wagoner J; Wanjalla CN; Masyuko S; Nyabiage J; Kinuthia J; Bloomfield GS; Page ST; Farquhar C
AIDS; 2021 Jan; 35(1):45-51. PubMed ID: 33055570
[TBL] [Abstract][Full Text] [Related]
7. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.
Kamat A; Misra V; Cassol E; Ancuta P; Yan Z; Li C; Morgello S; Gabuzda D
PLoS One; 2012; 7(2):e30881. PubMed ID: 22363505
[TBL] [Abstract][Full Text] [Related]
8. Monocyte Activation Is Associated With Worse Cognitive Performance in HIV-Infected Women With Virologic Suppression.
Imp BM; Rubin LH; Tien PC; Plankey MW; Golub ET; French AL; Valcour VG
J Infect Dis; 2017 Jan; 215(1):114-121. PubMed ID: 27789726
[TBL] [Abstract][Full Text] [Related]
9. Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIV.
Swanta N; Aryal S; Nejtek V; Shenoy S; Ghorpade A; Borgmann K
J Neurovirol; 2020 Jun; 26(3):358-370. PubMed ID: 32193795
[TBL] [Abstract][Full Text] [Related]
10. Plasma Cytokine Levels As Predictors of Global and Domain-Specific Human Immunodeficiency Virus-Associated Neurocognitive Impairment in Treatment-Naive Individuals.
Ruhanya V; Jacobs GB; Paul R; Joska J; Seedat S; Nyandoro G; Engelbrecht S; Glashoff RH
J Interferon Cytokine Res; 2021 Apr; 41(4):153-160. PubMed ID: 33885338
[TBL] [Abstract][Full Text] [Related]
11. Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1-Infected West African Adults With High CD4 Counts.
Affi R; Gabillard D; Dunyach-Remy C; Ntakpe JB; Moh R; Badje A; Kouame GM; Karcher S; Le Carrou J; Danel C; Chevalier MF; Rouzioux C; Eholie SP; Lavigne JP; Inwoley A; Anglaret X; Weiss L
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):138-145. PubMed ID: 33074857
[TBL] [Abstract][Full Text] [Related]
12. Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth.
Kapetanovic S; Leister E; Nichols S; Miller T; Tassiopoulos K; Hazra R; Gelbard HA; Malee KM; Kammerer B; Mendez AJ; Williams PL;
AIDS; 2010 Jun; 24(10):1481-91. PubMed ID: 20539091
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive function in HIV-infected patients with low weight and weight loss.
Dolan S; Montagno A; Wilkie S; Aliabadi N; Sullivan M; Zahka N; Sherman JC; Grinspoon S
J Acquir Immune Defic Syndr; 2003 Oct; 34(2):155-64. PubMed ID: 14526204
[TBL] [Abstract][Full Text] [Related]
14. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
[TBL] [Abstract][Full Text] [Related]
15. Peripheral immune dysregulation in the ART era of HIV-associated neurocognitive impairments: A systematic review.
Williams ME; Ipser JC; Stein DJ; Joska JA; Naudé PJW
Psychoneuroendocrinology; 2020 Aug; 118():104689. PubMed ID: 32479968
[TBL] [Abstract][Full Text] [Related]
16. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
[TBL] [Abstract][Full Text] [Related]
17. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
18. Elevated Plasma Levels of sCD14 and MCP-1 Are Associated With HIV Associated Neurocognitive Disorders Among Antiretroviral-Naive Individuals in Nigeria.
Jumare J; Akolo C; Ndembi N; Bwala S; Alabi P; Okwuasaba K; Adebiyi R; Umlauf A; Cherner M; Abimiku A; Charurat M; Blattner WA; Royal W
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):196-202. PubMed ID: 32084055
[TBL] [Abstract][Full Text] [Related]
19. Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.
Alcaide ML; Parmigiani A; Pallikkuth S; Roach M; Freguja R; Della Negra M; Bolivar H; Fischl MA; Pahwa S
PLoS One; 2013; 8(5):e63804. PubMed ID: 23724003
[TBL] [Abstract][Full Text] [Related]
20. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
